Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.33 |
| ▸ | CDK2 | P24941 | 3/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | PRUNE1 | Q86TP1 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK7 | P50613 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | CCNH | P51946 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.31 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.31 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.31 |
| ▸ | KHK | P50053 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20164708 | 0.99 | KCNH2 (0.34) | KCNH2CCNE1CDK2CDK5EGFR | |
| SCHEMBL20164493 | 0.86 | CDK1 (0.43) | CDK2EGFRPRUNE1CTNNB1TCF7L2 | |
| Hydrochloric Acid SCHEMBL20164490 | 0.85 | CDK1 (0.42) | CDK2EGFRPRUNE1CTNNB1TCF7L2 | |
| SCHEMBL20164646 | 0.83 | SLC29A1 (0.44) | CHRM4KHK | |
| Hydrochloric Acid SCHEMBL20164760 | 0.82 | SLC29A1 (0.43) | CHRM4KHK | |
| SCHEMBL20164612 | 0.81 | SLC29A1 (0.34) | — | |
| Hydrochloric Acid SCHEMBL20164691 | 0.80 | SLC29A1 (0.33) | — | |
| SCHEMBL20164337 | 0.80 | KHK (0.46) | KHK | |
| Hydrochloric Acid SCHEMBL20164662 | 0.79 | KHK (0.45) | KHK | |
| SCHEMBL20164718 | 0.76 | CDK2 (0.37) | CCNE1CDK2CDK5CCNT1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | NEURAD LTD. (IL) | 2018-05-24 | — | — | US | claimed |
| US-20250057848-A1 | GAL475 COMPOSITIONS AND METHODS OF USE THEREOF | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2025-02-20 | — | — | US | disclosed |
| EP-3316890-B1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME | NEURAD LTD (IL) | 2023-09-06 | — | — | EP | disclosed |
| US-10294228-B2 | Breathing control modulating compounds, and methods of making and using same | NEURAD LTD. (IL) | 2019-05-21 | — | — | US | disclosed |
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | NEURAD LTD. (IL) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | MTNR1B, CHRM3, PER2 | KCNH2 638/4885CCNE1 4167/4885CDK2 4026/4885 |
| US-20250057848-A1 | GAL475 COMPOSITIONS AND METHODS OF USE THEREOF | GPR119, GPR35, GPR55 | KCNH2 3213/4885CCNE1 2993/4885CDK2 3942/4885 |
| US-10294228-B2 | Breathing control modulating compounds, and methods of making and using same | MTNR1B, PDE3A, CHRM3 | KCNH2 847/4885CCNE1 4321/4885CDK2 4190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.